Literature DB >> 18035440

High grade glioma: imaging combined with pathological grade defines management and predicts prognosis.

Neil G Burnet1, Andrew G Lynch, Sarah J Jefferies, Stephen J Price, Phil H Jones, Nagui M Antoun, John H Xuereb, Ute Pohl.   

Abstract

INTRODUCTION: There is ambiguity in pathological grading of high grade gliomas within the WHO 2000 classification, especially those with predominant oligodendroglial differentiation. PATIENTS AND METHODS: All adult high grade gliomas treated radically, 1996-2005, were assessed. Cases in which pathology was grade III but radiology suggested glioblastoma (GBM) were classified as 'grade III/IV'; their pathology was reviewed.
RESULTS: Data from 245 patients (52 grade III, 18 grade III/IV, 175 GBM) were analysed using a Cox Proportional Hazards model. On pathology review, features suggestive of more aggressive behaviour were found in all 18 grade III/IV tumours. Oligodendroglial components with both necrosis and microvascular proliferation were present in 7. MIB-1 counts for the last 8 were all above 14%, mean 27%. Median survivals were: grade III 34 months, grade III/IV 10 months, GBM 11 months. Survival was not significantly different between grade III/IV and GBM. Patients with grade III/IV tumours had significantly worse outcome than grade III, with a hazard of death 3.7 times higher.
CONCLUSIONS: The results highlight the current inconsistency in pathological grading of high grade tumours, especially those with oligodendroglial elements. Patients with histological grade III tumours but radiological appearances suggestive of GBM should be managed as glioblastoma.

Entities:  

Mesh:

Year:  2007        PMID: 18035440     DOI: 10.1016/j.radonc.2007.10.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.

Authors:  Yosuke Watanabe; Fumiyuki Yamasaki; Yoshinori Kajiwara; Taiichi Saito; Takeshi Nishimoto; Chandra Bartholomeusz; Naoto T Ueno; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.

Authors:  Stanley Gu; Gargi Chakraborty; Kyle Champley; Adam M Alessio; Jonathan Claridge; Russell Rockne; Mark Muzi; Kenneth A Krohn; Alexander M Spence; Ellsworth C Alvord; Alexander R A Anderson; Paul E Kinahan; Kristin R Swanson
Journal:  Math Med Biol       Date:  2011-05-11       Impact factor: 1.854

3.  Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.

Authors:  Benjamin Lemasson; Thomas Christen; Xavier Tizon; Régine Farion; Nadège Fondraz; Peggy Provent; Christoph Segebarth; Emmanuel L Barbier; Philippe Genne; Olivier Duchamp; Chantal Remy
Journal:  NMR Biomed       Date:  2010-12-08       Impact factor: 4.044

4.  High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.

Authors:  M M Pike; C N Stoops; C P Langford; N S Akella; L B Nabors; G Y Gillespie
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

5.  Diagnostic challenges of primary thalamic gliomas-identification of a minimally enhancing neuroradiological subtype with aggressive neuropathology and poor clinical outcome.

Authors:  K M Kurian; Y Zhang; H R Haynes; N A Macaskill; M Bradley
Journal:  Clin Neuroradiol       Date:  2013-05-25       Impact factor: 3.649

6.  Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.

Authors:  Hyun Seok Choi; Ah Hyun Kim; Sung Soo Ahn; Na-young Shin; Jinna Kim; Seung-Koo Lee
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

7.  Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages.

Authors:  Eleonora Vannini; Federica Maltese; Francesco Olimpico; Alessia Fabbri; Mario Costa; Matteo Caleo; Laura Baroncelli
Journal:  Oncotarget       Date:  2017-04-04

8.  MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9.

Authors:  Nan Liu; Lei Zhang; Zhen Wang; Yingduan Cheng; Pengxing Zhang; Xin Wang; Weihong Wen; Hongwei Yang; Hui Liu; Weilin Jin; Yongsheng Zhang; Yanyang Tu
Journal:  Oncotarget       Date:  2017-03-21

9.  Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol.

Authors:  Paula B Dall'Stella; Marcos F L Docema; Marcos V C Maldaun; Olavo Feher; Carmen L P Lancellotti
Journal:  Front Oncol       Date:  2019-01-18       Impact factor: 6.244

10.  Clinical utility of arterial spin labeling for preoperative grading of glioma.

Authors:  Jun Fu; Linchen Li; Xinjun Wang; Min Zhang; Yan Zhang; Zhanzhan Li
Journal:  Biosci Rep       Date:  2018-08-31       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.